Clinical trial · Interventional
ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors
NCT01756989CI-TRIAL-00014451completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether initial local irradiation with topotecan and following oral antiangiogenic drugs, thalidomide, celecoxib and etoposide are effective in the treatment of pediatric diffuse brainstem tumor.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brainstem Glioma | Brain Stem Glioma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Thalidomide, etoposide, celecoxib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Thalidomide, etoposide, celecoxib
- description
- Single arm study,phase II
- interventionNames
- Drug: Thalidomide, etoposide, celecoxib
Primary outcomes (1)
- measure
- Survival
- timeFrame
- up to five years
- description
- Primary outcome measure is survival in months.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: -pediatric diffuse brainstem tumor Exclusion Criteria: * wish of the family * need for strong painrelievers * decreased level of consciousness * inability to swallow.
References
Publications (0)
Data not yet available
No reference posted for this study.